Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial

By sjmartinez • December 16, 2022

Podolanczuk AJ, Kim JS, Cooper CB, Lasky JA, Murray S, Oldham JM, Raghu G, Flaherty KR, Spino C, Noth I, Martinez FJ; PRECISIONS Study Team. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial. BMC Pulm Med. 2022 Dec 13;22(1):475. doi: 10.1186/s12890-022-02281-8. PMID: 36514019; PMCID: PMC9746571.

Tags: Clinical Trial, IPF, N-acetylcysteine, protocol, Publications, Pulmonary, Critical Care & Sleep Medicine

Host targets of candidalysin

Lin J, Filler SG. Host targets of candidalysin. PLoS Pathog. 2025 Jun 23;21(6):e1013284. doi: 10.1371/journal.ppat.1013284. PMID: 40549807; PMCID: PMC12184922.

Chimneys

Reuben DB. Chimneys. JAMA Intern Med. 2025 Jun 23. doi: 10.1001/jamainternmed.2025.1822. Epub ahead of print. PMID: 40549397.

Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in[...]